The person shown here is a basic user of this site. He or she may be contacted directly for language-related services.
|
Working languages: English to PanjabiPanjabi to EnglishHindi to English English to HindiPanjabi to HindiHindi to Panjabi
| Khushwant Singh
India Local time: 19:57 IST (GMT+5.5)
Native in: Panjabi  , Hindi | | Willingness to Work Again  |  No feedback collected |
| | |
|
| Freelancer | | Translation, Interpreting, Editing/proofreading, Website localization, Voiceover (dubbing), Subtitling, Post-editing, Transcription, Training, Desktop publishing, Project management, Vendor management, Sales, Operations management | | Specializes in: | | Accounting | Medical: Pharmaceuticals | | Marketing / Market Research | Law (general) | | Insurance | History | | General / Conversation / Greetings / Letters | Finance (general) | | Economics | Medical (general) |
| Also works in: | | Management | Business/Commerce (general) | | Computers (general) | Education / Pedagogy | | Real Estate | Internet, e-Commerce | | Astronomy & Space | Advertising / Public Relations | | Materials (Plastics, Ceramics, etc.) | Certificates, Diplomas, Licenses, CVs | | Poetry & Literature | Cinema, Film, TV, Drama | | Telecom(munications) | Textiles / Clothing / Fashion | | Engineering (general) | Energy / Power Generation | | Electronics / Elect Eng | Media / Multimedia | | Medical: Dentistry | Cosmetics, Beauty | | Cooking / Culinary | Food & Dairy | | Furniture / Household Appliances | Mining & Minerals / Gems | | Tourism & Travel | Medical: Health Care | | Human Resources | International Org/Dev/Coop | | Journalism | Military / Defense |
More Less | | Questions answered: 7, Questions asked: 48 | Sample translations submitted: 5 English to Panjabi: Medical Consent Forms (in Anmol Kalmi Font)
General field: Medical
Detailed field: Medical (general) | Source text - English
Patient Information Sheet
Introduction
You are invited to take part in a research study called ‘Sleep Apnea Cardiovascular Endpoints’ or ‘SAVE’, which is investigating the relationship between sleep and health. Before you decide to take part, it is important that you understand why this research is being conducted and what it will involve. Please take the time to read this document, and discuss it with your doctor, family or friends. If there is anything that is not clear, or if you would like more information, please ask your doctor or contact the person listed at the end of this document.
What is the purpose of the study?
Obstructive Sleep Apnea is a condition in which a person, because of relaxation of throat muscles, stops breathing for several seconds at a time, many times over, during sleep. Normally, a person is not aware of these obstructive episodes, but often family members may have noticed them occurring, along with loud snoring. The condition is very common and may cause sleepiness and poor concentration during the day. Research indicates that it may lead to high blood pressure and increase the risk of heart attacks and strokes, which are major causes of death and poor health in adults.
One of the current treatments available for Obstructive Sleep Apnea is the use of a small mask over the nose or nose and mouth, which people wear whilst they sleep. The mask is attached via a hose to a small machine, which gently pushes air into the lungs and allows people to continue breathing normally. This treatment is called Continuous Positive Airway Pressure, or CPAP. CPAP has been shown to effectively reduce snoring, obstructive episodes and daytime sleepiness. Some short-term research studies have shown that CPAP may help to reduce blood pressure.
The purpose of this study is to test if CPAP can help people with Obstructive Sleep Apnea and reduce the occurrence of heart attack, stroke or heart failure, or reduce factors such as blood pressure, blood sugar and cholesterol levels that may predispose to these events.
Why have I been chosen?
You have been asked to participate in this research as you may be at ‘higher-than-normal’ risk of having Obstructive Sleep Apnea. This is because you have certain factors, such as a previous heart attack , angina, coronary artery disease requiring bypass graft surgery, angioplasty or stenting, stroke, or transient ischaemic attack (“TIA”, or “mini-stroke”) We hope to involve several thousand people ( approximately 5000 people) from around the world in this study.
What are the study procedures?
If you agree to participate in this study, you will first be asked to undergo an interview by trained research staff to provide answers to a series of questions about your health, medical history, and sleeping habits. If the results of this interview are satisfactory you will next need to have your breathing monitored overnight in your home. You will be provided with a small device that you will connect to yourself prior to going to sleep. This device will record your breathing and blood oxygen levels whilst you sleep. This is not painful. We will ask you to return to the clinic so that we can assess the recording. There is a very small chance that the study would have to be repeated if there are problems with the recording.
If the monitoring confirms that you do have Obstructive Sleep Apnea, you will be invited to participate in the next part of the study, which is evaluating the effects of CPAP on cardiovascular disease. Treatment with CPAP involves wearing a mask over your nose alone, or nose and mouth, whilst you sleep. This mask is connected to a small pump which gently pushes air into your nose/mouth under pressure and keeps your airways open, allowing you to breathe normally whilst you are asleep.
In order to assess how well you are able to use CPAP, the treatment will be offered to you over an initial period of 1-2 weeks using a CPAP device that generates little or no pressure. The purpose of this initial so-called ‘run-in phase’ is simply to see how well you adapt to the mask treatment and whether it is likely you can succeed in using such a treatment over the next 3-5 years of follow-up in the study. CPAP in the run-in phase is not expected to reverse your snoring or sleep apnea.
After one week of the home CPAP run-in phase you will be asked to return to the clinic in the morning with the machine and mask. If the recording device in the CPAP machine shows you have achieved an appropriate high level of use of CPAP you will be asked to continue into the next phase of the study. If the recording device shows you have not achieved a sufficiently high use of the CPAP mask you may be invited to try the CPAP again for another 1-2 weeks at home after first ensuring the mask fit and adjustment is optimal and any other problems you may have had with the mask are addressed.
If all your results are satisfactory and you agree to proceed to the next, long-term follow-up, phase of the study you will immediately have a blood sample taken which will be stored for future exploratory analyses of chemical factors that might give important clues as to how Obstructive Sleep Apnea predisposes to heart attacks and strokes. The volume of this blood sample will be approximately 10 ml (about 2 teaspoons). You will also be asked to agree to have approximately 10 ml of blood taken for genetic (DNA) testing to investigate the role of genes in Obstructive Sleep Apnea and cardiovascular diseases. A separate Patient Information and Consent form is provided for the DNA testing part of the study. Refusing to give a sample for DNA testing will not stop you from being in the study. The blood specimens for DNA and other analyses will only be used in relation to this study and when they are no longer required, they will be disposed of by the Laboratory according to usual policy guidelines.
All participants will then be required to undergo a brief physical examination to measure blood pressure, heart rate, height, weight, and neck size. An electrocardiogram (ECG, to trace the heart rhythm) will be ordered to assess the functioning of the heart. You will also complete questionnaires about your sleep and general health and well-being. .
You will then be randomly allocated (like the toss of a coin) to either receive treatment with CPAP, or to continue with your usual medical care. There is a 50% chance of being assigned to either group. All people involved will receive advice about Obstructive Sleep Apnea and some simple measures that can be taken to improve symptoms. People allocated to receive their usual care will continue to have their normal treatment as directed by their regular doctor. This study will not interfere with any important medications that you may be taking for reasons outside the study.
Those patients randomly allocated to receive CPAP treatment will have a 1-2 week home trial of a special (“auto”) CPAP device that continuously and automatically adjusts and records the mask pressure needed during sleep to keep your throat open. After this 1-2 week trial period you will return to the clinic and this information will be used to set an appropriate fixed pressure level in a new CPAP machine which will be given to you to use long-term at home.
All people involved in the long-term follow-up part of the study will be asked to attend the clinic at 1, 3, 6 and 12 months, and then 6 monthly for the next 3-5 years,(the length of the follow-up period will depend on when you are first enrolled in the study). Each visit will last approximately 45 minutes, and will involve the research staff taking a medical history (with specific questions about your sleep), completing a medical examination, and performing simple investigations such as a heart tracing (electrocardiogram or ECG).
At the end of the study, there should be no further reason to contact you. At some time, though, further research may be undertaken into Obstructive Sleep Apnea and CPAP, at which point you may be invited to participate further. There would be no obligation to participate at any stage of either study.
What are the benefits?
CPAP therapy is known to improve symptoms of sleepiness in people who suffer from Obstructive Sleep Apnea. Additionally, it is hoped that this study will add to the existing evidence showing that CPAP helps to improve high blood pressure, particularly in Asian people in whom high blood pressure is common and where there is very limited use of CPAP therapy. In the longer term, it is hoped that CPAP will prevent people with Obstructive Sleep Apnea from developing cardiovascular diseases such as heart attacks and strokes. If this trial is successful, we will conduct further research in this area.
If you have used CPAP for the duration of the study and wish to continue using the device after the study finishes, then you will be able to keep you CPAP device at no cost. If you were randomly allocated to the patient group that received usual care and the study shows that CPAP reduces the risk of cardiovascular disease, you will, at the end of the study also be eligible to receive a CPAP device free of cost.
Are there any risks?
Some patients who are shown by the simple home sleep test to have obstructive sleep apnea may have mild to moderate daytime sleepiness that could improve with CPAP treatment. In this study, which is focussed on cardiovascular health, such patients, if randomly allocated to receive usual care, could miss out on a symptom benefit. If you are found to have obstructive sleep apnea and feel excessively sleepy you may wish to consider the option of CPAP treatment outside this trial. You are a free to do so, or to seek an independent opinion from your doctor or sleep specialist before making a decision whether or not to enrol in the study. If you decide to enrol in the study you will be monitored at regular intervals with respect to your level of sleepiness. If we find evidence that it is reaching a level that we consider poses a risk for a fall-asleep accident you will be withdrawn from the study and advised to seek independent medical advice and treatment. If at any time you consider yourself unsafe because of excessive sleepiness you should report this immediately to the research staff.
CPAP is a very safe treatment. However, all medical procedures – whether for diagnosis or treatment, routine or experimental – involve some risk. In addition, there may be risks associated with this study that are presently unknown and unforeseeable. In spite of all precautions, it is possible that you might develop a medical complication from participating in this study. The risks of participating in this study include:
• bruising from the blood sample
• CPAP
o irritation of the eyes and the skin on the face;
o leaks of air around the mask because it does not fit properly;
o nasal congestion, runny nose, and sneezing;
o abdominal bloating;
Occasionally, the humming noise of the CPAP machine is troublesome to the person or to family members. If you do suffer any of the above side effects of CPAP, please discuss with the trial staff before ceasing treatment, as the mask, air humidity and pressure may be able to be adjusted to a comfortable level.
Finally it is important to be aware that no medical treatment is ever 100% effective, and the use of CPAP for cardiovascular disease is relatively new and untested. Thus despite use of CPAP or other treatments as part of your usual health care, your blood pressure or risk factors (i.e. cholesterol, diabetes) may not improve and you could still suffer a heart attack or stroke, or other ill-health.
Are there any costs or compensation for participating and injuries or complications?
There are no costs to you to be involved in this research.
If you suffer any injuries or complications as a result of this study, you should contact the study doctor as soon as possible, who will assist you in arranging appropriate medical treatment.
In the unlikely event of a physical injury as a result of your participation in this trial, you may be covered by an insurance policy. If you have any questions about this, contact the investigator.
Will my information be confidential?
All information gathered about you during the study will be kept strictly confidential. Only the SAVE researchers will have access to your medical records, in order to check the accuracy of the information collected and to ensure that this study is being carried out appropriately.
Any information transferred electronically will be coded to protect your confidentiality. All computer records will be password protected. Study documentation will be kept and securely archived for at least 15 years.
The results of this study may be presented at medical conferences and published in scientific journals. No material that could identify you personally will be used in any reports on this study. All information gathered about you during the study will be available to you upon request.
Do I have to take part?
Participation in this study is entirely voluntary: you are not obliged to participate and - if you do participate - you can withdraw at any time, without explanation. Whatever your decision, it will not affect your usual medical treatment or your relationship with medical staff.
If you decide to participate, you will be asked to sign a consent form. You will be given signed copies of the consent form and this information sheet to keep.
Who is conducting this study?
The study is being conducted by an international group of researchers based in China, Europe, the United States of America, India and Australia.
Who can I contact for further details?
If you have any questions or concerns after reading this information and discussing with your doctor, please contact the following person:
Investigator:
Telephone number:
Who has approved this study?
This study has received Approval from the following Ethics Committee:
________________________________(Name of the Ethics Committee)
Any person with concerns or complaints about the conduct of a research study can contact the following person: Member Secretary of the Ethics Committee on
_______________________(Telephone Number)
| Translation - Panjabi
mrIz dI jwxkwrI vwlI sihmqI SIt
BUimkw
quhwnUM iek Koj AiDAYn ivc ih~sw lYx leI s~dw id~qw jw irhw hY ijs nUM ‘slIp ApnyAw kwrfIEvYskUlr AYNfpWiets’ jW ‘AYs ey vY eI (SAVE)’ kihMdy hn, jo nINd Aqy ishq ivckwr dy irSqy dI jWc kr rhI hY[ies qoN pihlW ik qusIN Bwg lYx dw PYslw kro, quhwfy leI ieh smJxw mh~qvpUrn hY ik ieh vwDU Koj ikauN ho rhI hY Aqy ies ivc kI Swiml hovygw[ ikRpw krky ies dsqwvyz nUM pVHx leI smW lvo, Aqy Awpxy fwktr, pirvwr jW dosqW nwl ies bwry ivcwr vtWdrw kro[ jy koeI cIz sp~St nhIN hY, jW jy qusIN hor jwxkwrI lYxI cwhuMdy ho, ikRpw krky Awpxy fwktr nUM pu~Co jW ies dsqwvyz dy AKIr ivc d~sy ivAkqI nwl sMprk kro[
AiDAYn dw kI audyS hY?
Abstr~kitv slIp ApnyAw iek AvsQw hY ijs ivc iek ivAkqI nINd dy dOrwn, keI vwrI, gly dIAW nwVIAW dy iF~ly pYx kwrn, iek smyN qy kuJ sikMtW leI swh lYxw bMd kr idMdw hY[ Awm qOr qy, ivAnqI nUM ienHW rukwvtI GtnwvW bwry pqw nhIN huMdw, pr Aksr pirvwr dy mYNbr aucI GrwiVAW dy kwrn ies dw vwprnw noits krdy hn[ ieh AvsQw bhuq hI Awm hY Aqy ies dy kwrn idn ivc nINd dw Awauxw Aqy kmzor XwdwSq ho skdI hY[ Koj drswauNdI hY ik ies nwl v~D bl~f pRYSr ho skdw hY Aqy idl dy dOry Aqy sdmy dw Kqrw v~D skdw hY, jo bwlgW ivc kmzor ishq Aqy mOq dy mu~K kwrn hn[
Abstr~kitv slIp ApnyAw dy mOjUdw ielwzW ivcoN iek ielwz hY, iek Cotw mwsk n~k auqy jW n~k Aqy mUMh auqy vrqxw, ijs nUM ivAkqI nINd dy smyN pihx skdy hn[ ieh mwsk n~k duAwrw iek CotI mSIn nwl juiVAw huMdw hY jo hOlI hOlI hvw nUM PyPiVAW ivc Awrwm nwl D~kdI hY Aqy ivAkqIAW nUM Awrwm nwl swh zwrI r~Kx dI iezwjq idMdI hY[ ies ielwz nUM lgwqwr skwrwqmk vwXUmwrg dbwA jW sI pI ey pI (CPAP) kihMdy hn[sI pI ey pI (CPAP) ny GrwiVAW, rukwvtI GtnwvW Aqy idn dy smyN nINd Awaux nUM pRBwvSwlI qrIky nwl Gtxw dyiKAw igAw hY[ kuJ CotI AvDI dy Koj AiDAYnW ivc dyiKAw igAw hY ik sI pI ey pI (CPAP) bl~f pRYSr nUM Gtwaux ivc mdd kr skdw hY[
ies AiDAYn dw audyS ieh jWcxw hY ik kI sI pI ey pI (CPAP) Abstr~kitv slIp ApnyAw nwl dy ivAkqIAW dI mdd kr skdI hY Aqy idl dy dOry, sdmy jW idl dy Pyl hox dIAW GtnwvW dy vwprx nUM Gtw skdI hY, jW kwrkW nUM ijvyN ik bl~f pRYSr, bl~f SUgr Aqy kolystrol dy sqr GtwauNdw hY ijnHW dw ienHW GtnwvW v~l Jukwau ho skdw hY[
mYnUM ikauN cuixAw igAw hY?
quhwnUM ies AiDAYn ivc Bwg lYx leI ikhw jw irhw hY ikauNik quhwnUM ‘Awm – nwloN – v~D’ Abstr~kitv slIp ApnyAw dw Kqrw ho skdw hY[ ieh ies krky hY ikauNik quhwfy kol kuJ kwrk hn, ijvyN ik ipClw idl dw dOrw, AynzInw, koronrI AwrtrI ibmwrI ijs nUM bweIpws grwPt srzrI dI zrUrq hY, AynijEplwstI jW stYnitMg, sdmw, jW trWisMt iecyimk AtYk (“tI AweI ey (TIA)” jW “Cotw sdmw”)[ swnUM ies AiDAYn ivc dunIAW Br qoN keI sO hzwr lokW (lgBg 5000 lokW dI) dy Swiml hox dI aumId hY[
AiDAYn dIAW ikhVIAW kwrj pRxwlIAW hn?
jy qusIN ies AiDAYn ivc Bwg lYx leI sihmq ho, quhwnUM pihlW isiKAq Koj stwP duAwrw iek ieMtrivaU ivc quhwfI ishq, mYfIkl ieiqhws, Aqy nINd dIAW AwdqW bwry svwlW dI lVI dw jvwb dyx leI ikhw jwvygw[ jy ies ieMtrivaU dy nqIzy qs~lIbKS hn qW A~gy quhwnUM quhwfy Gr ivc swrI rwq swh mwpx dI zrUrq hovygI[ quhwnUM iek Cotw aupkrx id~qw jwvygw ijs nUM qusIN sOx qoN pihlW Awpxy nwl joVogy[ ieh aupkrx quhwfy swh qy KUn ivclI AwksIjn dy sqr nUM irkwrf krygw jdoN qusIN so rhy hovogy[ ieh drdnwk nhIN hY[ AsIN quhwnUM klIink ivc vwips Awaux leI khWgy qW jo AsIN irkwrf qw phuMc kr skIey[ ies dw bhuq hI G~t Avsr hn ik AiDAYn nUM dubwrw duhrwieAw jwvy jy irkwrifMg krn ivc muSiklW hox[
jy mwp puStI krdw hY ik quhwnUM Abstr~kitv slIp ApnyAw hY, qW quhwnUM AiDAYn dy Agly ih~sy ivc Bwg lYx leI s~dw id~qw jwvygw, jo sI pI ey pI (CPAP) dy kwrfIEvYskUlr ibmwrIAW auqy pRBwv dw mulWkx krygw[sI pI ey pI (CPAP) dy ielwz ivc quhwfy sox dy smyN, iek~ly n~k qy, jW n~k Aqy mUMh au~pr iek mwsk pihnxw Swiml hY[ ieh mwsk iek Coty pMp nwl juiVAw hY jo hvw nUM holI holI quhwfy n~k/ mUMh ivc pRYSr nwl D~kygw Aqy quhwfy vwXU mwrg nUM KolH ky r~Kdw hY, Aqy quhwfy sox dy smyN quhwnUM Awrwm nwl swh lYx dI AwigAw dy irhw hY[
ies kRm dw inrDwrn krn leI ik qusIN ikMnI cMgI qrHW nwl sI pI ey pI (CPAP) nUM vrqx dy Xog ho, quhwnUM ielwz dy 1-2 hPiqAW dy SurUAwqI smyN dOrwn ielwz dy leI iek sI pI ey pI (CPAP) aupkrx vrqx leI id~qw jwvygw jo QoVw ijhw jW koeI vI pRYSr auqpMn nhIN krdw[ies SurUAwqI ijs nUM ‘rn-ien Pyz’ vI kihMdy hn dw audyS swDwrx qOr qy ieh dyKxw hY ik qusIN mwsk dy ielwz nwl ikMnI cMgI qrHW nwl AnukUl ho Aqy ies dI ikMnI sMBwvnw hY ik AiDAYn ivc ies qrHW dy ielwz dI vrqoN dy Agly 3-5 swl qk Anukrx krn ivc ikMny sPl huMdy ho[ rn- ien Pyz ivc sI pI ey pI (CPAP) nwl quhwfy GrwiVAW jW slIp ApnyAw dy aultx dI koeI aumId nhIN hY[
GrylU sI pI ey pI (CPAP) rn-ien Pyz dy iek hPqy bwAd quhwnUM svyr dy smyN mSIn Aqy mwsk dy nwl klIink ivc Awaux leI ikhw jwvygw[ jy sI pI ey pI (CPAP) mSIn ivcly irkwrifMg aupkrx qoN pqw cldw hY ik qusIN sI pI ey pI (CPAP) dI vrqoN dw auicq vwDU sqr pRwpq kr ilAw hY quhwnUM AiDAYn dy Agly Pyz ivc zwrI rihx leI ikhw jwvygw[jy sI pI ey pI (CPAP) mSIn ivcly irkwrifMg aupkrx qoN pqw cldw hY ik qusIN sI pI ey pI (CPAP) mwsk dI vrqoN dw auicq vwDU sqr nhIN pRwpq kIqw hY qW quhwnUM sI pI ey pI (CPAP) nUM hor 1-2 hPiqAW leI Gr ivc dubwrw vrqx leI bulwvw id~qw jw skdw hY, ieh suinSicq krn qoN bwAd ik mwsk iPt hY Aqy smwDwn auicq hY Aqy koeI vI hor muSiklW jo quhwnUM mwsk nwl ho cu~kIAW hn dw iviKAwn ho cu~kw hY[
jy quhwfy swry nqIzy sMqoSjnk hn Aqy qusIN A~gy v~Dx leI rwzI ho, AiDAYn dy lMby smyN dy Pwlo-Ap Pyz leI, quhwfy qoN qurMq hI iek KUn dw nmUnw ilAw jwvygw jo Biv~K ivc rswienk kwrkW dI jWc pVqwl krn leI stor krky r~iKAw jwvygw jo mh~qvpUrn surwg dy skdy hn ik ikvyN Abstr~kitv slIp ApnyAw dw idl dy dOirAW Aqy sdimAW vl Jukwau bxdw hY[ies KUn dy nmUny dI mwqrw lgBg 10 im.lI. (2 cwh dy cmc) hovygI[quhwnUM ieh jWc krn leI ik zIns dI Abstr~kitv slIp ApnyAw Aqy kwrfIEvYskUlr ibmwrIAW ivc kI Buimkw hY dy vwsqy AnuvMiSk (fI AYn ey) jWc leI lgBg 10 im.lI. dI mwqrw ijMnw KUn dyx dI sihmqI dyx leI vI ikhw jwvygw[ AiDAYn dy fI AYn ey jWc vwly ih~sy leI iek Al~g mrIz dI jwxkwrI Aqy sihmqI Pwrm pRdwn kIqw jwvygw[fI AYn ey jWc leI nmUny dyx qoN ienkwr krn nwl quhwfI AiDAYn ivc SmUlIAq bMd nhIN ho jwvygI[fI AYn ey leI KUn dy nmUny Aqy hor ivSlySxW nUM kyvl ies AiDAYn dy sMbMD ivc hI vriqAw jwvygw Aqy jdoN ienHW dI zrUrq pYxI bMd ho jwvygI, ienHW nUM Awm pwilsI idSw inrdySW dy Anuswr pRXogswlw duAwrw nSt kr id~qw jwvygw[
swry BwgIdwrW nUM aus qoN bwAd bl~f pRYSr, idl dI gqI, lMbweI, Bwr, Aqy gly dy Awkwr nUM mwpx leI iek CotI ijhI srIrk jWc leI jwxw pvygw[ idl dy kwrjW dw mulWkx krn leI iek ielYktRokwrfIEgrwm (idl dI lYA dw pqw lgwaux leI, eI sI jI) krn dw AwdyS id~qw jwvygw[ quhwnUM quhwfI nINd Aqy Awm ishq Aqy qMdrusqI nwl sMbMiDq iek pRSnwvlI nUM pUrw krnw hovygw[
aus qoN bwAd quhwnUM byqrqIby FMg nwl (ijvyN ik is~ky nUM auCwlxw) jW qW sI pI ey pI (CPAP) dy nwl ielwz imlygw, jW quhwnUM quhwfI Awm mYfIkl dyKBwl dy nwl hI zwrI rihx id~qw jwvygw[ iksy vI gru~p ivc Awaux dw 50% mOkw hY[ swry Swiml ivAkqIAW nUM Absr~kitv slIp ApnyAw Aqy kuJ swDwrx qrIky jo l~CxW nUM suDwrx leI vrqy jw skdy hn dy bwry slwh imlygI[ ijnHW ivAkqIAW nUM aunHW dI Awm mYfIkl dyKBwl lYxI inXq hoeI hY, auh aunHW dy fwktr duAwrw d~sy swDwrn ielwz nUM jwrI r~Kxgy[ ieh AiDAYn iksy vI mh~qvpUrn dvweI jo qusIN AiDAYn qoN bwhrly iksy vI kwrn krky lY rhy ho skdy ho, nwl dKl AMdwzI nhIN krygw[
auh mrIz ijnHW nUM byqrqIby FMg nwl sI pI ey pI (CPAP) dw ielwz imlxw inXq hoieAw hY, nUM 1-2 hPiqAW leI Gr ivc pRXog krn leI iek ivSyS (“svY-cwilq”) sI pI ey pI (CPAP) aupkrx imlygw jo lgwqwr Aqy Awpxy Awp mwsk dy pRYSr nUM irkwrf krygw Aqy quhwfy gly nUM KulHw r~Kx leI ijMnI zrUrq huMdI hY nUM ivvsiQq krygw[ ies 1-2 hPiqAW dI pRXoigk AvDI qoN bwAd quhwnUM klIink ivc vwips Awauxw pvygw Aqy ies jwxkwrI nUM nvIN sI pI ey pI (CPAP) mSIn ivc auicq inSicq pYRSr dw sqr inXq krn leI vriqAw jwvygw, jo quhwnUM Gr ivc lMby smyN qk vrqx leI id~qI jwvygI[
swry ivAkqI jo AiDAYn dy lMby smyN dy AnuvrqI ih~sy ivc Swiml hn, nUM 1, 3, 6 Aqy 12 mhIinAW qy, Aqy iPr Agly 3-5 swlW leI hr 6 mhIny bwAd klIink ivc Awaux leI ikhw jwvygw (Anukrx AvDI dI lMbweI ies g~l qy inrBr krygI ik qusIN AiDAYn ivc pihlW kdoN nwm drz krwieAw sI)[ hr mulwkwq lgBg 45 imMtW dI hovygI, Aqy Koj stwP duAwrw quhwfy mYfIkl ieiqhws nUM mMgxw Swiml hovygw (ivSyS qOr qy quhwfI nINd bwry svwl), iek mYfIkl inrIKx nUM pUrw krnw, Aqy swDwrx jWcW krnIAW ijvyN ik idl dw AnuryKx krnw (ielYktrokwrfIEgRwm jW eI sI jI)[
AiDAYn dy AMq ivc, quhwnUM sMprk krn dw A~gy koeI vI kwrn nhIN hoxw cwhIdw hY[ kuJ smyN qy, iPr vI, Absr~kitv slIp ApnyAw Aqy sI pI ey pI (CPAP) ‘qy A~gy Koj kIqI jw skdI hY, aus qy quhwnUM A~gy Bwg lYx leI bulwvw id~qw jw skdw hY[ iksy vI AiDAYn dy iksy vI sqr qy quhwnUM Bwg lYx dI koeI vI bMidS nhIN hovygI[
kI lwB hn?
sI pI ey pI (CPAP) ielwz nINd dy l~CxW nUM suDwrx leI jwixAw jWdw hY jo Absr~kitv slIp ApnyAw qoN pIiVq hn[ ies qoN ielwvw, ieh aumId kIqI jWdI hY ik ieh AiDAYn mOjUdw sbUqW nUM A~gy vDweygw jo ieh idKwauNdy hn ik sI pI ey pI (CPAP) v~D bl~f pRYSr nUM suDwrx ivc mdd krdw hY, Kws qOr qy eySIAn mUl dy lokW ivc ijnHW ivc v~D bl~f pRYSr Awm hY aqy ijQy sI pI ey pI (CPAP) ielwz dI vrqoN bhuq hI sIimq hY[ lMby smyN ivc, ieh aumId kIqI jWdI hY ik sI pI ey pI (CPAP) Abstr~kitv slIp ApnIAw nwl dy ivAkqIAW ivc kwrfIEvYskUlr ibmwrIAW nUM ivkisq hox qoN rokx ivc mdd krygI ijvyN ik idl dy dOry Aqy sdmy[ jy ieh pRXog sPl ho jWdw hY, qW AsIN ies Kyqr ivc A~gy hor Koj krvwvWgy[
jy qusIN AiDAYn dy dOrwn sI pI ey pI (CPAP) dI vrqoN kIqI hY Aqy AiDAYn Kqm hox qoN bwAd vI aupkrx dI vrqoN nUM zwrI r~Kxw cwhuMdy ho, qW qusIN sI pI ey pI (CPAP) aupkrx nUM ibnW iksI mu~l dy Awpxy kol r~K skdy ho[ jy qusIN byqrqIby FMg nwl aunHW mrIzW dy gru~p ivc cly gey ho jo Awm dyKBwl lYNdy hn Aqy AiDAYn idKwauNdw hY ik sI pI ey pI (CPAP) kwrfIEvYskUlr ibmwrI dy Kqry nUM GtwauNdw hY, qusIN vI, AiDAYn dy Kqm hox qy ibnW iksy mu~l dy sI pI ey pI (CPAP) aupkrx lYx dy leI Xog ho[
kI koeI Kqry hn?
kuJ mrIj ijnHW ivc Awm GrylU nINd jWc (simple home sleep test) duAwrw Abstr~kitv slIp ApnIAw dyiKAw igAw hY, nUM G~t qoN QoVI izAwdw idn vyly nINd Aw skdI hY ijs nUM sI pI ey pI (CPAP) dy ielwz nwl suDwirAw jw skdw hY[ ies AiDAYn ivc, ijs dw kyNdr kwrfIEvYskUlr ishq hY, aunHW mrIzW nUM, jy au~GV FuGVy FMg nwl swDwrx dyKBwl id~qI jwvy, qW l~CxW dy lwB krky AsPl ho skdI hY[ jy quhwnUM l~gdw hY ik quhwnUM Abstr~kitv slIp ApnyAw hY Aqy bhuq izAwdw nINd mihsUs huMdI hY qW qusIN ies inrIKx qoN bwhroN sI pI ey pI (CPAP) dw ielwz krwaux dy ivklp leI ivcwr kr skdy ho[ qusIN ies qrHW krn leI Awzwd ho, jW ieh PYslw lYx qoN pihlW ik qusIN AiDAYn ivc ih~sw lYxw hY ik nhIN, qusIN Awpxy fwktr jW nINd dy ivSySg qoN suqMqr rwey lY skdy ho[ jy qusIN AiDAYn ivc ih~sw lYx de PYslw lYNdy ho qW quhwfy nINd dy sqr dI jWc inXimq AMqrwl qy hovygI[ jy swnUM sbUq imldw hY ik ieh aus sqr qy phuMc geI hY ijs ivc swfy ivcwr Anuswr nINd Awaux nwl durGtnw dw Kqrw hY quhwnUM AiDAYn ivcoN bwhr k~F id~qw jwvygw Aqy slwh id~qI jwvygI ik qusIN suqMqr icikqskI slwh lvo Aqy ielwz krvwE[ jy quhwnUM iksy vI smyN ieh ivcwr AwauNdw hY ik qusIN izAwdw nINd dy kwrn Awpxy Awp nUM Asur~iKAq mihsUs krdy ho qusIN qurMq ies dI irport Koj stwP nUM kro[
sI pI ey pI (CPAP) iek bhuq hI sur~iKAq ielwz hY[ iPr vI, swrIAW icikqskI kwrj pRxwlIAW – BwvyN l~Bx leI jW ielwz leI, in~q jW pRXogwqmk – nwl kuJ Kqry Swiml huMdy hn[ ies qoN ielwvw, ies AiDAYn nwl sMbMiDq Kqry ho skdy hn jo ik mOjUdw siQqI ivc Ax-pCwqy Aqy AigAwq hn[ swrIAW swvDwnIAW vrqx dy bwvzUd, ies g~l dI sMBwvnw hY ik ies AiDAYn ivc Bwg lYx nwl quhwnUM mYfIkl sm~isAwvW ivkisq ho jwx[ ies AiDAYn ivc Bwg lYx dy KqirAW ivc Swiml hn:
• KUn dy nmUny qoN JrIt l~gxI
• sI pI ey pI (CPAP)
• A~KW Aqy ichry dI cmVI qy JuMJlwht hoxI;
• mwsk dy Awly duAwly qoN hvw dw lIk hoxw ikauiNk ieh TIk FMg nwl iPt nhIN hoieAw;
• n~k ivc sMkuln, n~k dw v~gxw, Aqy in~CW mwrnIAW;
• pyt dw su~jnw;
keI vwrI, sI pI ey pI (CPAP) mSIn dI iBMniBMnwht vwlI Awvwz ivAkqI leI jW pirvwr dy mYNbrW leI kStdweI ho skdI hY[ jy quhwnUM au~pr d~isAW ivcoN sI pI ey pI (CPAP) dy koeI vI gOx pRBwv huMdy hn, ikRpw krky ielwz bMd krn qoN pihlW inrIKx stwP nwl ivcwr kr lvo, ikauN jo, mwsk, hvw ivclI nmIN Aqy dbwA nUM Awrwmdyh sqr qk ivvsiQq kIqw jw skdw hY[
Amq ivc ies bwry pqw hoxw zrUrI hY ik koeI vI icikqskI ielwz hmySW 100% pRBwvSwlI nhIN huMdw, Aqy kwrfIEvYskUlr dI ibmwrI leI sI pI ey pI (CPAP) dI vrqoN nvIN Aqy AxprKI hY[ ies krky quhwfI Awm ishq sMBwl dy ih~sy vzoN sI pI ey pI (CPAP) jW hor ielwzW dI vrqoN dy bwvjUd, quhwfy bl~f pRYSr jW hor joiKm kwrkW (kolystrol, fwieibits) ivc suDwr nhIN vI ho skdw hY Aqy quhwnUM iPr vI idl dw dOrw jW sdmw ho skdw hY, jW hor Krwb ishq ho skdI hY[
kI Bwg lYx leI koeI lwgqW jW muAwvzy Aqy s~tW jW sm~isAwvW hn?
ies AiDAYn ivc Swiml hox leI quhwfy qy koeI lwgqW nhIN hn[
jy quhwnUM ies AiDAYn dy nqIzy vzoN koeI s~tW jW sm~isAwvW huMdIAW hn, qW quhwnUM ijMnI jldI sMBv hovy AiDAYn fwktr nUM sMprk krnw cwhIdw hY, jo quhwnUM auicq icikqskI ielwz dw pRbMD krn ivc mdd krngy[
ies inrIKx ivc BwgIdwrI dy nqIzy vzoN hoeI srIrk cot dI du~Kd Gtnw ivc qusIN iek bImw pwilsI duAwrw sur~iKAq ho skdy ho[ jy quhwnUM ies bwry koeI pRSn hn qW jWckrqw nUM sMprk kro[
kI myrI jwxkwrI gupq hovygI?
AiDAYn dy dOrwn quhwfy bwry iek~TI kIqI swrI jwxkwrI nUM sKqI nwl gupq r~iKAw jwvygw[ ieh dyKx leI ik iek~TI kIqI jwxkwrI shI hY Aqy ieh XkInI bnwaux leI ik ieh AiDAYn auicq FMg nwl kIqw jw irhw hY, kyvl AYs ey vI eI (SAVE) KojIAW dI hI quhwfy mYfIkl irkwrfW qk phuMc hovygI[ quhwfI gupqqw nUM bcwaux leI iksy vI jwxkrI nUM ielYktroink FMg nwl Byjx leI aus nUM kof lgwieAw jwvygw[ swry kMipaUtr irkwrf pwsvrf nwl sur~iKAq hoxgy[ AiDAYn dsqwvyz G~to G~t 15 swl leI r~Ky Aqy sMBwly jwxgy[
ies AiDAYn dy nqIzy mYfIkl kwnPrMsW ivc pyS kIqy jw skdy hn Aqy ivigAwink mYgzInW ivc pRkwiSq kIqy jw skdy hn[ koeI vI sm~grI jo quhwfI ivAkqIgq pCwx dsdI hY nUM ies AiDAYn dI iksy vI irport ivc nhIN vriqAw jwvygw[ AiDAYn dOrwn quhwfy bwry iek~TI kIqI swrI jwxkwrI quhwnUM mMgx qy id~qI jw skdI hY[
kI mYnUM Bwg lYxw pvygw?
ies AiDAYn ivc BwgIdwrI pUrI qrHW nwl svYieiC~q hY[ quhwnUM BwgIdwrI leI koeI bMidS nhIN hY – jy qusIN Bwg lYNdy ho – qusIN iksy vI smyN ibnW koeI sp~StIkrn id~qy, bwhr ho skdy ho[ quhwfw jo vI PYslw hovygw, ieh quhwfI Awm mYfIkl dyKBwl jW mYfIkl stwP nwl quhwfy sMbMDW nUM pRBwivq nhIN krygw[
jy qusIN Bwg lYx dw PYslw krdy ho, quhwnUM iek sihmqI Pwrm qy dsqKq krn leI ikhw jwvygw[ quhwnUM sihmqI Pwrm dIAW dsqKq kIqIAW kwpIAW Aqy ieh jwxkwrI SIt r~Kx leI id~qI jwvygI[
ies AiDAYn nUM kOx krvw irhw hY?
ies AiDAYn nUM cIn, Xorp, XUnweIitf styts AwP AmrIkw (AmrIkw), Bwrq Aqy AstrylIAw dy KojIAW dw iek AMqr-rwStrI gru~p krvw irhw hY[
vDyry jwxkwrI leI mYN iks nUM sMprk kr skdw hW?
jy quhwnUM ies jwxkwrI nUM pVx Aqy Awpxy fwktr nwl ivcwr vtWdrw krn qoN bwAd koeI svwl jW SMkw hn, qW ikRpw krky hyTW ilKy ivAkqI nUM sMprk kro:
jWckrqw:
tYlIPon nMbr:
ies AiDAYn nUM iks duAwrw mwnqw pRwpq hY?
ies AiDAYn nUM hyTW ilKI AYiQks kmytI duAwrw mwnqw pRwpq hY:
________________________ (AYiQks kmytI dw nwm)
koeI vI ivAkqI ijs nUM Koj AiDAYn dy pRbMDn bwry SMkw jW svwl hn, hyTW ilKy ivAkqI nUM sMprk kr skdw hY: AYiQks kmytI dw mYNbr sYktrI ______________________ (tYlIPon nMbr) ‘qy[
| English to Panjabi: Medical Consent Form (In Anmol Kalmi font)
General field: Medical
Detailed field: Medical: Health Care | Source text - English
Informed Consent – SAVE Trial
Site Name: ________________________________
Name of Researcher: ________________________________________________
I confirm that I ………………………………………………………………(name)
• have read and understand the Patient Information Sheet (Version …..dated …….. ) for the above named research study and have discussed the study with ……………………;
• have had any questions or queries answered to my satisfaction;
• understand that my participation is voluntary and that I am free to withdraw at any time, without giving any reason, without my medical care or legal rights being affected;
• have been informed of any known or expected inconvenience, risk, discomfort or potential side effects of involvement in the study;
• have been informed that the confidentiality of the information will be maintained and safeguarded;
• give permission for access to my medical records, for the purpose of this research;
• give permission for medical practitioners, other health professionals, hospitals or laboratories outside this centre, to release de-identified information concerning my disease and treatment, and understand that such information will remain confidential;
• give permission to have tests performed as outlined in the Patient Information Sheet, including a brief physical examination, an electrocardiogram, blood samples and monitoring of my sleep overnight;
• understand the compensation provisions for this study;
• have been informed of whom to contact if I have any questions about the study;
• understand that for the duration of the study any CPAP equipment I may receive as part of the trial remains the property of the study investigators, and if I do not intend to continue using CPAP the equipment must be returned;
• understand that following completion of the study I will be responsible for the future maintenance and repair of any CPAP equipment that is given to me.
I hereby consent to take part in this research.
___________________ ___________________
Signature (or Thumb Impression)of Participant Date (day/month/year)
e.g,. 14 July 2003
___________________Printed Name of Participant
I have witnessed and certify the Participant’s oral consent whether or not he/she voluntarily agrees to participate in this research trial.
___________________
Signature of Legally Acceptable Representative
(to be completed only if the participant
cannot read the patient
information sheet)
___________________
Date (day/month/year)
e.g,. 14 July 2003
___________________
Printed name of Legally Acceptable Representative
___________________
Relationship to the Participant
The Participant’s confirmation is attested by the above signature of a Legally Acceptable Representative.
I have witnessed and certify the Participant’s oral consent whether or not he/she voluntarily agrees to participate in this research trial.
___________________ ___________________
Signature of Impartial Witness Date (day/month/year)
(to be completed only if the participant e.g,. 14 July 2003
cannot read the patient
information sheet)
___________________ ___________________
Printed name of Impartial Witness Relationship to the Participant
The Participant’s confirmation is attested by the above signature of an Impartial Witness.
___________________
Signature of person administering informed consent
___________________
Date (day/month/year)
e.g,. 14 July 2003
___________________Printed name of person administering informed consent
| Translation - Panjabi
jwxkwrI vwlI sihmqI – AYs ey vI eI (SAVE)inrIKx
sweIt dw nwm: ________________________________
AiDAYn krqw dw nwm: ________________________________________________
mYN puStI krdw hW ik mYN ……………………………… (nwm)
• auprly nwm vwly Koz AiDAYn dI mrIz dI jwxkwrI vwlI SIt (vrzn ……. imqI …………) pVH Aqy smJ leI hY Aqy …………….. nwl AiDAYn bwry ivcwr vtWdrw kr ilAw hY;
• iksy vI svwl jW pRSn dw jvwb myrI sMquStI Anuswr idqw igAw hY;
• smJdw hW ik AiDAYn ivc myrI BwgIdwrI svYieCk hY Aqy mYN iksy vI smyN koeI kwrn d~sy bgYr, myrI icikqskI sMBwl jW kwnUMnI h~kW dy pRBwivq hoey bgYr bwhr inklx leI Awzwd hW;
• AiDAYn ivc ih~sw lYx kwrn hox vwlI iksy vI jwxU jW sMBwivq AsuivDw, Kqry, kSt jW sMBwivq gOx pRBwvW dI jwxkwrI idqI jw cu~kI hY;
• jwxkwrI idqI jw cu~kI hY ik jwxkwrI dI gopnIAqw sMBwlky Aqy sur~iKAq r~KI jwvygI;
• ies AiDAYn dy audySW leI, Awpxy icikqskI irkwrfW qk phuMc dI AwigAw id~qI hY;
• icikqsk AiBAwsI, hor ishq dy pySwvr, ies kyNdr qoN bwhrly hspqwl jW pRXogswlwvW nUM myrI ibmwrI Aqy ielwz sMbMiDq pCwx mukq jwxkwrI nUM jwrI krn dI AwigAw id~qI hY, Aqy smJdw hW ik ies jwxkwrI nUM gupq r~iKAw jwvygw;
• srIrk inrIKx, ielYktrokwrfIEgRwm, KUn dy nmUny, Aqy myrI swrI rwq dI nINd dy inrIKx smyq mrIz dI jwxkwrI vwlI SIt ivc d~sy prIKxW nUM krn dI AwigAw id~qI hY;
• ies AiDAYn leI muAwvzy dIAW ivvsQwvW nUM smJdw hW;
• jy AiDAYn sMbMDI myry koeI svwl hn qW iks nUM sMprk krnw hY bwry jwxkwrI id~qI jw cu~kI hY;
• smJdw hW ik AiDAYn dy dOrwn koeI vI sI pI ey pI aupkrx jo mYnUM inrIKx dy ih~sy vzoN iml skdy hn, AiDAYn jWckrqwvW dI sMpqI rihxgy, Aqy jy mYN sI pI ey pI dI vrqoN zwrI nWh r~Kx dw ierwdw krdw hW, qW aupkrx vwps krny pYxgy;
• smJdw hW ik AiDAYn pUrw hox qoN bwAd, jo sI pI ey pI aupkrx mYnUM id~qy gey hn, dI Biv~K ivc sWB sMBwl Aqy murMmq dI izMmyvwrI myrI hovygI[
mYN ies AiDAYn ivc ih~sw lYx leI sihmq hW[
----------------------------- ------------
BwgIdwr dy dsqKq (jW AMgUTy dy inSwn) im~qI (idn/ mhInw/ swl)
audwhrx vzoN, 14 julweI 2003
______________________ BwgIdwr dw CipAw hoieAw nwm
mYN gvwhI idMdw hW Aqy BwgIdwr dI mUMh zbwnI sihmqI nUM pRmwixq krdw hW ik auh svYieiCq qOr qy ies AiDAYn inrIKx ivc Bwg lYx leI sihmq hY jW nhIN[
_________________
kwnUMn duAwrw svIikRq numwieMdy dy dsqKq
(kyvl qW hI pUrw kIqw jwvy jy BwgIdwr
mrIz dI jwxkwrI vwlI SIt
nUM pVH nhIN skdw)
____________
im~qI (idn/ mhInw/ swl)
audwhrx vzoN, 14 julweI 2003
_________________
kwnUMn duAwrw svIikRq numwieMdy dw CipAw hoieAw nwm
_________________
BwgIdwr nwl irSqw
BwgIdwr dw puStIkrn au~pr id~qy kwnUMn duAwrw svIikRq numwieMdy dy dsqKq duAwrw pRmwixq hY[
mYN gvwhI idMdw hW Aqy BwgIdwr dI mUMh zbwnI sihmqI nUM pRmwixq krdw hW ik auh svYieiCq qOr qy ies AiDAYn inrIKx ivc Bwg lYx leI sihmq hY jW nhIN[
_________________ _______________
inrp~K gvwh dy dsqKq im~qI (idn/ mhInw/ swl)
(kyvl qW hI pUrw kIqw jwvy jy BwgIdwr audwhrx vzoN, 14 julweI 2003
mrIz dI jwxkwrI vwlI SIt
nUM pVH nhIN skdw)
_________________ _________________
inrp~K gvwh dw CipAw hoieAw nwm BwgIdwr nwl irSqw
BwgIdwr dw puStIkrn au~pr id~qy inrp~K gvwh dy dsqKq duAwrw pRmwixq hY[
_____________________
jwxkwrI vwlI sihmqI dw pRbMD krn vwly dy dsqKq
____________
im~qI (idn/ mhInw/ swl)
audwhrx vzoN, 14 julweI 2003
______________ jwxkwrI vwlI sihmqI dw pRbMD krn vwly dw CipAw hoieAw nwm
| English to Panjabi: Legal Notice (In AnmolKalmi font)
General field: Law/Patents
Detailed field: Law (general) | Source text - English
IN THE HIGH COURT OF JUSTICE Claim No:
QUEEN’S BENCH DIVISION
BEFORE THE HONOURABLE MR JUSTICE
BETWEEN
Claimant
And
Defendant
ORDER
BEFORE The Honourable Mr Justice [ ] sitting in [ ] on [ ]
UPON HEARING [ ] one of Her Majesty’s Counsel, on behalf of the Claimant and [ ] one of Her Majesty’s Counsel, on behalf of the Defendant
UPON READING the matters recited below namely the Order of Mr ………………….. (“the substituted Order”) which is by agreement of the parties varied by way of complete substitution by this Order, the Joint Opinion of Edwards Faulks QC and Edward Bishop dated [ ] and the advice of Ian Gunn dated [ ]
WHEREAS the Claimant has made a claim (the “Claim”) against the Defendant for personal injuries suffered by her arising out of the Defendant’s negligence on or about 26 December 1997 and in respect of which proceedings were commenced by the Claimant against the Defendant in the High Court of Justice Queens Bench Division on 6 October 2006
AND WHEREAS the Claimant is a child and protected party proceeding through her Aunt and Litigation Friend, Mrs Ranjit Nagra
AND WHEREAS Judgment was entered for the Claimant with damages to be assessed on 17 October 2006
AND WHEREAS the National Health Service Litigation Authority (“NHSLA”) or its successors shall be responsible for and make the payments set out in the Schedule to this Order and for the benefit of the Claimant (referred to below as “periodical payments”)
AND WHEREAS the NHSLA has entered into an agreement with the Defendant which permits the NHSLA to be responsible for and make the periodical payments under this Order
AND WHEREAS the NHSLA is a Special Health Authority within the meaning of the National Health Services (Residual Liabilities) Act 1996
AND WHEREAS the Defendant and the NHSLA agree with the Claimant that in the event of any failure to make the periodical payments or any alteration in the method or change in the identity of the source of payment the same shall give rise to a direct right of the Claimant to enforce this Order and all rights arising under it against the NHSLA in consideration of the Claimant agreeing to the terms of this Order
AND UPON the Court being satisfied that:
(a) The continuity of payments under the Order is reasonably secure pursuant to section 2(3) of the Damages Act 1996 (as amended) because the source of payment is an NHS body namely the NHSLA within the meaning of section 2(4)(c) of the Act by virtue of the Damages (Government and Health Service Bodies) Order 2005) and under the terms of the Order as herein set out
(b) The periodical payments are to be paid free of taxation under section 731-734 of the Income Tax (Trading and Other Income) Act 2005
(c) The Order set out below is agreed by the Claimant and the Defendant as being the preferred Order that should apply
(d) The form of the Order is that which best meets the Claimant’s needs and CPR 21 and 41 have been complied with
AND UPON the Claimant having given the following undertakings to the Court
1. A Deputy has been appointed for the Claimant.
2. The Claimant whether acting by her Litigation Friend or her Deputy will take all necessary steps to seek to stay the claim and any proceedings which have begun or have been threatened against the Defendant in connection with the Claim
3. The Claimant, her Litigation Friend and/or her Deputy will not institute any proceedings against the Defendant or any other party or person whomsoever in connection with the Claim save by way of enforcement of this Order
AND UPON the parties having agreed in full and final settlement of the claim that the Defendant shall pay to the Claimant the sum of ……………………………… inclusive of any interim payments and CRU together with the periodical payments contained in the Schedule annexed to this Order
AND UPON the Court having approved the terms of this Order and the Schedule annexed to this Order
| Translation - Panjabi
dwAvw nM.:
jsits kUeIns bYNc ifvIzn dI hweI kort ivc
Awnrybl SImwn j~j dy A~gy
ivckwr
dwAvydwr
Aqy
pRqIvwdI
AwdyS
mwnXog j~j im. { } dy A~gy [ } ivc bYTy { } qy
suxvweI qy { } dwAvydwr vloN, mhwrwxI dy vkIlW ivcoN iek Aqy { } pRqIvwdI vloN, mhwrwxI dy vkIlW ivcoN iek
AiDAYn qy hyTW idqy mwmilAW dw vrxn kIqw hY Bwv j~j …………………….. nUM muhrbMd kIqy (“pRqIsQwipq AwdyS”) jo ik iDrW dy rwjInwmy nwl ies hukm dy pUrI qrHW pRqIsQwipq krn dy iviBMn rUp ivc, eIfvrfs Polks ikaU sI Aqy eIfvrf ibSp dI sWJI rwey imqI { } Aqy ieAwn gn dI slwh imqI { }
prMqU dwAvydwr ny pRqIvwdI dy ivruD 26 dsMbr 1997 nUM pRqIvwdI dI AxgihlI krky in~jI nukswn Bugqx leI dwAvw (“dwAvw”) kIqw hY Aqy ijs dI bwbq pRqIvwdI duAwrw dwAvydwr dy ivruD j~j kUeIns bYNc ifvIjn dI hweI kort ivc 6 AkqUbr 2006 nUM kwrvweI SurU kIqI sI
Aqy jdoN pRqIvwdI b~cw hY Aqy sur~iKAq pwrtI kwrvweI aus dI AWtI Aqy muk~dmybwj dosq, imsz rxjIq nwgrw duAwrw kIqI
Aqy jdo dwAvydwr leI PYslw drz kIqw igAw Aqy nukswn inrDwrx 17 AkqUbr 2006 nUM hovygw
Aqy jdo nYSnl hYlQ srivs iltIgySn AQwirtI (“NHSLA”) jW ies dy au~qriDkwrI ies AwdyS dy nwl sUcI ivc vrxn Bugqwn leI Aqy krn leI Aqy dwAvydwr dy lwB leI izMmyvwr hoxgy (hyTW ies qrHW aulyK krnw “inXqkwlI AdwiegIAW”)
Aqy jdo NHSLA pRqIvwdI nwl krwr krdI hY jo iejwzq idMdI hY NHSLA ies AwdyS dy ADIn inXqkwlI AdwiegIAW leI Aqy krn leI izMmyvwr hY
Aqy jdo NHSLA nYSnl hYlQ srivs (rYzIfUAl lwieibiltI) AYkt 1996 dy ArQW ivc iek Kws ishq AQwirtI hY
Aqy jdo NHSLA Aqy pRqIvwdI dwAvydwr nwl rwzI ho jWdy hn ik koeI vI inXqkwlI AdwiegIAW nw krn dI sUrq ivc jW qrIky ivc iksy vI qbdIlI jW AdwiegI dy sroq dI pCwx ivc bdlwA dwAvydwr nUM ieh AwdyS lwgU krn leI is~Dw AiDkwr pYdw krygw Aqy NHSLA dy ivruD swry AiDkwr ies AwdyS dIAW SrqW qy rwzI hox dy dwAvydwr dy ivcwr nwl ies dy hyTW pYdw huMdy hn
Aqy aupr Adwlq sMquSt hY ik:
(a) fYmyizs AYkt 1996 (ijvyN bdilAw) dI Dwrw 2(3) dy Anuswr AwdyS dy ADIn Bugqwn dw islislw auicq FMg nwl sur~iKAq hY ikauNik Bugqwn dw sRoq iek NHS bwfI hY ArQwq NHSLA AYkt dI Dwrw 2(4)(C) dy ArQW dy ADIn fYmyizs (gvrnmYNt AYNf hYlQ srivs bwfIs) AwdyS 2005) dy kwrn Aqy ieQy inrDwrq AwdyS dIAW SrqW dy ADIn
(A) inXqkwlI AdwiegIAW ienkm tYks (tryifMg AYNf Adr ienkm) AYkt 2005 dI Dwrw 731-734 dy ADIn kr mukq idqIAW jwxgIAW
(e) dwAvydwr Aqy pRiqvwdI hyTW inrDwrq AwdyS qy rwzI hn ies leI psMdIdw AwdyS dy qOr qy lwgU hovygw
(s) AwdyS dw Pwrm aus qrHW huMdw hY jo dwAvydwr dIAW jrUrqW nUM au~qm FMg nwl pUrw krdw hY Aqy CPR 21 Aqy 41 dI qwmIl krdw hY
Aqy aupr dwAvydwr ny hyTly vcn Adwlq nUM idqy:
1. dwAvydwr vwsqy iek ifptI dI inXukqI
2. dwAvydwr cwhy Awpxy mukdmybwj dosq jW ifptI duAwrw ikRAwSIl hovy auh dwAvy ivc rihx leI jrUrI kdm qlwS skdw hY Aqy koeI kwnUMnI kwrvweI jo SurU kIqI geI hY jW DmkI jo dwAvy dy sMbMD ivc pRqIvwdI dy ivruD hY
3. dwAvydwr ausdI mukdmybwj dosq jW ausdI ifptI pRqIvwdI dy ivruD jW iksy hor iDr jW koeI ivAkqI jo ies dwAvy dy AwdyS nUM lwgU krn ivc sMbMiDq hY koeI kwrvweI dwier nhI krygI
Aqy aupr iDrW pUrI Aqy AMiqm dwAivAW nUM qih krn leI rwzI hn pRqIvwdI dwAvydwr nUM ………………………. dw Bugqwn krygw Aqy koeI vI AMqirm Bugqwn Aqy CRU iek~Ty AwdyS dI AnusUcI ivc n~QI inXqkwlI AdwiegIAW nwl Swiml hn
Aqy aupr Adwlq ny ies AwdyS dIAW SrqW nUM pRvwngI idqI hY Aqy ies AwdyS nUM AnusUcI nwl n~QI kIqw hY
| English to Panjabi: General Letter/Advt. of a School
General field: Other
Detailed field: General / Conversation / Greetings / Letters | Source text - English
Graduation Rate
• Continue to utilize data systems that support a realistic diagnosis of the number of students who drop out and that help identify individual students at high risk of dropping out.
• Assign adult advocates to students at risk of dropping out.
• Provide academic support and enrichment to improve academic performance.
• Implement programs to improve students’ classroom behavior and social skills.
• Personalize the learning environment and instructional process.
• Provide rigorous and relevant instruction to better engage students in learning and provide skills needed to graduate and to serve them after leaving school.
Special Education Reading Subgroup
• Continue to utilize data and assessment systems to diagnosis individual student reading levels and deficiencies.
• Through the Individual Educational Program (IEP) process and in conjunction with the English/Reading Department, develop, implement, and monitor a reading intervention program for each identified student.
• Identify and implement additional reading intervention programs to address the needs of this subgroup as well as students in other subgroups identified for reading intervention programs.
• Provide advocacy and opportunities for each student and family in order to develop an educational partnership between the family and the school that engages each student in the full school program.
School-wide
• Continue to maintain and monitor high standards for rigorous academic, athletic, and social participation within the school community.
• Continue to provide high quality professional development designed to foster continuous self-evaluation of teaching and learning.
• Monitoring of Measurable Objectives in all subjects.
• Providing college-based experiences through relationships with institutions of higher education.
• Develop collaborative teaching teams and common planning periods as well as engage in vertical teaming activities with feeder elementary and middle schools.
• Advancement Through Individual Determination (AVID) strategies infused into and aligned with Voluntary state Curriculum.
• Provide opportunities for extended day/year activities for academic and enrichment support.
• Active involvement and participation of the Leadership/School Improvement Team for instructional decision making.
| Translation - Panjabi
ਸਨਾਤਕ ਦਰ
• ਉਨ੍ਹਾਂ ਡੇਟਾ ਪ੍ਰਣਾਲੀਆਂ ਦੀ ਵਰਤੋਂ ਜਾਰੀ ਰੱਖਣਾ ਜੋ ਉਨ੍ਹਾਂ ਸਭਨਾਂ ਵਿਦਿਆਰਥੀਆਂ ਦੀ ਵਾਸਤਵਕ ਤਸ਼ਖੀਸ ਲਈ ਸਮਰਥਨ ਦਿੰਦੀਆਂ ਹਨ ਜੋ ਪਡ਼੍ਹਾਈ ਛੱਡ ਦਿੰਦੇ ਹਨ ਅਤੇ ਜੋ ਪਡ਼੍ਹਾਈ ਛੱਡਣ ਦੇ ਜੋਖੋਂ ਵਜੋਂ ਵਿਅਕਤੀਗਤ ਵਿਦਿਆਰਥੀਆਂ ਦੀ ਪਛਾਣ ਵਿੱਚ ਮਦਦ ਕਰਦੀਆਂ ਹਨ।
• ਪਡ਼੍ਹਾਈ ਛੱਡ ਜਾਣ ਦੇ ਜੋਖੋਂ ਵਜੋਂ ਵਿਦਿਆਰਥੀਆਂ ਲਈ ਨੌਜਵਾਨ ਵਕੀਲਾਂ ਦੀ ਨਿਯੁਕਤੀ ਕਰਨਾ।
• ਵਿੱਦਿਅਕ ਪਰਦਰਸ਼ਨ ਨੂੰ ਸੁਧਾਰਨ ਲਈ ਵਿੱਦਿਅਕ ਸਮਰਥਨ ਅਤੇ ਸੰਪੰਨਤਾ ਪਰਦਾਨ ਕਰਨਾ।
• ਵਿਦਿਆਰਥੀਆਂ ਦੇ ਕਲਾਸ-ਰੂਮ ਵਿੱਚ ਸ਼ਿਸ਼ਟਾਚਾਰ ਅਤੇ ਸਮਾਜਕ ਮੁਹਾਰਤਾਂ ਨੂੰ ਸੁਧਾਰਨ ਲਈ ਕਾਰਜਕ੍ਰਮ ਲਾਗੂ ਕਰਨਾ।
• ਸਿੱਖਿਅਕ ਵਾਤਾਵਰਣ ਅਤੇ ਉਪਦੇਸ਼ ਪਰਕਿਰਿਆ ਨੂੰ ਵਿਅਕਤੀਗਤ ਰੂਪ ਦੇਣਾ।
• ਸਿੱਖਿਆ ਨਾਲ ਵਿਦਿਆਰਥੀਆਂ ਨੂੰ ਬੇਹਤਰ ਢੰਗ ਨਾਲ ਜੁਡ਼ਣ ਵਜੋਂ ਕਰਡ਼ੇ ਅਤੇ ਢੁੱਕਵੇਂ ਨਿਰਦੇਸ਼ ਦੇਣਾ ਅਤੇ ਗਰੈਜੂਏਸ਼ਨ ਲਈ ਲੋਡ਼ੀਂਦਾ ਕੁਸ਼ਲਤਾਵਾਂ ਪਰਦਾਨ ਕਰਨਾ ਅਤੇ ਸਕੂਲ ਛੱਡਣ ਤੋਂ ਬਾਅਦ ਵੀ ਉਨ੍ਹਾਂ ਦੀ ਰੱਖਵਾਲੀ ਕਰਨਾ।
ਵਿਸ਼ੇਸ਼ ਸਿੱਖਿਆ ਅਧਿਐਨ ਉੱਪਸਮੂਹ
• ਵਿਅਕਤੀਗਤ ਵਿਦਿਆਰਥੀ ਦੇ ਅਧਿਐਨ ਸੱਤਰ ਅਤੇ ਕਮੀਆਂ ਦੀ ਤਸ਼ਖੀਸ ਕਰਨ ਲਈ ਡੇਟਾ ਅਤੇ ਵਿਸ਼ਲੇਸ਼ਣ ਦੀ ਵਰਤੋਂ ਕਰਨਾ ਜਾਰੀ ਰੱਖਣਾ।
• ਵਿਅਕਤੀਗਤ ਵਿੱਦਿਅਕ ਕਾਰਜਕ੍ਰਮ (IEP) ਪ੍ਰਣਾਲੀ ਅਤੇ ਅੰਗ੍ਰੇਜ਼ੀ/ਅਧਿਐਨ ਵਿਭਾਗ ਨਾਲ ਸਬੰਧ ਦੁਆਰਾ ਹਰ ਇੱਕ ਸ਼ਨਾਖਤੀ ਵਿਦਿਆਰਥੀ ਲਈ ਇੱਕ ਅਧਿਐਨ ਦਖਲ ਕਾਰਜਕ੍ਰਮ ਦਾ ਵਿਕਾਸ, ਲਾਗੂ ਅਤੇ ਨਿਰੀਖਣ ਕਰਨਾ।
• ਅਧਿਐਨ ਰੁਕਾਵਟ ਕਾਰਜਕ੍ਰਮਾਂ ਲਈ ਪਛਾਣੇ ਗਏ ਦੂਜੇ ਉੱਪਸਮੂਹਾਂ ਦੇ ਵਿਦਿਆਰਥੀਆਂ ਦੇ ਨਾਲ-ਨਾਲ ਇਸ ਉੱਪਸਮੂਹ ਦੀ ਜਰੂਰਤਾਂ ਨੂੰ ਸੰਬੋਧਤ ਕਰਨ ਲਈ ਵਾਧੂ ਅਧਿਐਨ ਰੁਕਾਵਟ ਕਾਰਜਕ੍ਰਮਾਂ ਦੀ ਸ਼ਨਾਖਤ ਅਤੇ ਲਾਗੂ ਕਰਨਾ।
• ਪਰਵਾਰ ਅਤੇ ਸਕੂਲ ਦੇ ਵਿੱਚਕਾਰ ਇੱਕ ਵਿੱਦਿਅਕ ਸਾਂਝੇਦਾਰੀ ਨੂੰ ਵਿਕਸਤ ਕਰਨ ਲਈ ਹਰ ਇੱਕ ਵਿਦਿਆਰਥੀ ਅਤੇ ਪਰਵਾਰ ਲਈ ਮੌਕੇ ਅਤੇ ਵਕਾਲਤ ਪਰਦਾਨ ਕਰਨਾ।
ਸਕੂਲ-ਵਿਆਪੀ
• ਸਕੂਲ ਦੇ ਅੰਦਰ ਕਰਡ਼ੀ ਵਿੱਦਿਅਕ, ਕਸਰਤੀ, ਸਮਾਜਕ ਭਾਈਵਾਲੀ ਲਈ ਉੱਚੇ ਮਾਨਕਾਂ ਨੂੰ ਬਣਾਏ ਰੱਖਣਾ ਅਤੇ ਉਨ੍ਹਾਂ ਦਾ ਨਿਰੀਖਣ ਜਾਰੀ ਰੱਖਣਾ।
• ਅਧਿਆਪਨ ਅਤੇ ਸਿੱਖਿਆ ਦੇ ਲਗਾਤਾਰ ਸਵੈ-ਮੁਲਾਂਕਣ ਨੂੰ ਅਗਾਂਹ ਵਧਾਉਣ ਲਈ ਤਿਆਰ ਕੀਤਾ ਉੱਚੀ ਕਵਾਲਟੀ ਦਾ ਕਾਰੋਬਾਰੀ ਵਿਕਾਸ ਪਰਦਾਨ ਕਰਨਾ।
• ਸਭਨਾਂ ਵਿਸ਼ਿਆਂ ਵਿੱਚ ਅਨੁਮਾਨ ਯੋਗ ਉਦੇਸ਼ਾਂ ਦਾ ਨਿਰੀਖਣ ਕਰਨਾ।
• ਉੱਚੀ ਸਿੱਖਿਆ ਪ੍ਰਣਾਲੀ ਦੀਆਂ ਸੰਸਥਾਵਾਂ ਨਾਲ ਸਬੰਧ ਸਥਾਪਤ ਕਰਕੇ ਕਾਲਜ-ਆਧਾਰਤ ਤਜ਼ਰਬੇ ਪਰਦਾਨ ਕਰਨਾ।
• ਸਹਿਯੋਗੀ ਅਧਿਆਪਨ ਟੀਮਾਂ ਅਤੇ ਆਮ ਯੋਜਨਾ ਸਮੇਂ ਦੇ ਨਾਲ ਨਾਲ ਖੁਰਾਕ ਤੱਤਾਂ ਅਤੇ ਮਿਡਲ ਸਕੂਲਾਂ ਨਾਲ ਸਿਖਰਲੀ ਸਮੂਹਕ ਕਿਰਿਆਵਾਂ ਨਾਲ ਸਬੰਧ ਵਿਕਸਤ ਕਰਨਾ।
• ਵਿਅਕਤੀਗਤ ਦਰਿਡ਼੍ਹਤਾ ਵਜੋਂ ਤਰੱਕੀ (ਐਡਵਾਂਸਮੈਂਟ ਥਰੂ ਇਨਡਿਵਿਡਵਲ ਡਿਟਰਮਿਨੇਸ਼ਨ) (AVID) ਦੀਆਂ ਨੀਤੀਆਂ ਨੂੰ ਸਵੈ-ਇੱਛਤ ਪਰਦੇਸ਼ ਪਾਠਕ੍ਰਮ ਦੇ ਨਾਲ ਸੰਚਾਰਨ ਅਤੇ ਲਾਗੂ ਕਰਨਾ।
• ਵਿੱਦਿਅਕ ਅਤੇ ਉੰਨਤੀ ਸਮਰਥਨ ਲਈ ਵਿਸਤਰਤ ਦਿਨ/ਸਾਲ ਦੀਆਂ ਕਿਰਿਆਵਾਂ ਲਈ ਮੌਕੇ ਪਰਦਾਨ ਕਰਨਾ।
• ਵਿੱਦਿਅਕ ਫੈਂਸਲੇ ਲੈਣ ਲਈ ਅਗਵਾਈ/ਸਕੂਲ ਸੁਧਾਰਕ ਟੀਮ ਦੀ ਸਾਂਝੀਦਾਰੀ ਅਤੇ ਕਿਰਿਆਸ਼ੀਲ ਭਾਗੀਦਾਰੀ।
| English to Panjabi: Sub-titling work
General field: Other
Detailed field: Cinema, Film, TV, Drama | Source text - English
Sub-Titling work | Translation - Panjabi
• ਇਹ ਬਰਫ਼ਾਨੀ ਸੜਕ ਦਾ 20ਵਾਂ ਸਾਲ ਹੈ...
• ਕਠਿਨ ਦੰਡ ਭਰੇ ਨਵੇਂ ਮੌਸਮ ਨੂੰ 2 ਦਿਨ।
• ਭਾਰ ਨੂੰ ਅੱਗੇ ਵਧਾਉਣ ਦਾ ਸਮਾਂ...
• ...ਭਾਰ ਨੂੰ ਅੰਦਰ ਕਰੋ, ਮੋਟਾ ਪੈਸਾ ਕਮਾਓ।
• 750 ਟਰੱਕ ਸੜਕ ਤੇ ਚਲ ਚੁੱਕੇ ਹਨ,
• ਜੰਮੀ ਝੀਲ ਤੇ 60 ਟਨ ਭਾਰ ਦੀ ਬਰਾਬਰੀ ਦੇ ਭਾਰ ਨੂੰ ਖਿੱਚਣਾ।
• ਸਰਦ ਤੁਫਾਨਾਂ ਨਾਲ ਲੜਣਾ,
• ਢਹਿ ਢੇਰੀ ਅਤੇ ਕਮਜ਼ੋਰ ਕਰਨ ਵਾਲੀ ਠੰਢ – 55 ਡਿਗਰੀ।
• ਪਵਿੱਤਰ ਜ਼ੀਸਸ!
• - ਕੋਈ ਜ਼ੈਕਪਾਟ ਜਿਤੇਗਾ – ਪੈਸਾ!
• - ਕੋਈ ਮੁੱਠੇਦਾਰ ਚਾਕੂ – ਇਹ ਬਹੁਤ ਚੰਗੀ ਸਥਿਤੀ ਨਹੀ ਹੈ।
• ਅਤੇ ਦੂਸਰੇ ਤਾਂ ਗੇਟ ਤੋਂ ਬਾਹਰ ਵੀ ਨਹੀਂ ਆ ਸਕੇ।
|
More Less | | Years of translation experience: 6. Registered at ProZ.com: May 2007. | | N/A | | N/A | | N/A | | Adobe Acrobat, Frontpage, Microsoft Excel, Microsoft Word, Powerpoint, SDL TRADOS | | English (DOC), English (DOC) | | About me Doing Translation work, Validation and Proof Reading (our specialization), Content writing, Adaptation & Localization work, Voice over and typing work as a Freelancer since 2004.
• Presently working on project of translating Canada based Multinational bank’s website (since October 2009).
• Presently working as TLE (Target language Expert for Punjabi & Hindi language) for formulating/designing passages/text/teaching & study material for learning purposes for a US based university (since August 2009).
• Presently working on Adaptation project with UK based agency for Multi National Brand’s Advertisements (both audio-visual and Press advt.) for Punjabi & Hindi languages. This project includes Adaptation and direction of Voice-Over recording.
• Presently working on 2 projects with 2 Linguist agencies (U.K. based) for transcribing and translating from Punjabi and Hindi to English. Total time 200 hours
Also conducted Research Work in Medical & clinical field (as I’ve good relations with Doctors and author of Medical Text books and other persons in Medical industry) and Market research.
Language pair is: Punjabi – English; Hindi – English; English – Punjabi; English – Hindi; Hindi - Punjabi.
Area of specialisation: Clinical & Medical,Technical, Scientific, IT related, Social Sciences, Legal subjects and also in Advertising, Publishing, Entertainment (Movies). And Translation of books, project/annual reports, legal documents (contracts), Localization of Web content/advertisements etc.
Rates: Rs 1.50 per word to Rs 4 per word for Translation (Negotiable)
Rs 0.75 per word to Rs 1.50 per word for Proof-reading and Validation work
(Depends upon the quantity of work and Time).
Daily Output: 1500 to 2500 words per day (can give more output in case of urgency).
Mode of Payment: Fund Transfer and/or through Cheque.
|
|
Keywords: Translation from Punjabi to English, Translation from Punjabi to Hindi, Translation from English to Hindi, Translation from English to Punjabi, Translation from Hindi to English, Translation from Hindi ti Punjabi; Proof-Reading in Hindi, Proof-reading in Punjabi, Proof-Reading in English;Children's Books and short stories;Proof-Reading of novels, stories, articles and books.
Profile last updated
Jan 26 |
The translation workplace 
Expertise